Across TCGA pan-cancer cohorts, NOG mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NOG data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NOG mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NOG expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC and LUAD are the cancer types where NOG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.867	0.304	.002	16	view →
LUAD	DFS	Quartile	All	1.000	0.370	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: NOG tumor-vs-normal RNA expression · all NOG data types